The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Tyler Van Buren - Cowen and Company LLC - Analyst
: Hey guys, thanks very much for the presentation. Certainly, a lot to consider across the indications. But I guess based upon George's comments
just now, do you guys ultimately expect the SAFER A2 antibody to be the larger product? And what do you think needs to be shown in terms of
improvement in bleeding in the pivotal trials? Is there a numerical bar you're looking for? Or will it be powered for statistical significance?
Question: David Risinger - Leerink Partners LLC - Analyst
: Thanks very much and thanks for hosting this session today. So how do you think about the magnitude of Factor XI inhibition that is required to
match Factor Xa apixaban efficacy and atrial fibrillation. And can you please reframe the inhibition that 7508 delivers relative to 993?
Question: Simon Baker - Rothschild & Company Redburn - Analyst
: Thank you for taking my question and thanks so much for hosting this call. In the Lancet paper that was published with this data, the authors
highlight the potential for 9933 in preventing medical device triggered clotting, which is induced by Factor XI activation. Is that an area of interest,
it doesn't appear explicitly in the development program. I'm wondering if maybe by prespecified subgroups, you might be able to assess that in
some of the studies. But any thoughts on the attractiveness of that would be much appreciated.
Question: William Pickering - Sanford C Bernstein & Co LLC - Analyst
: Hi, thank you for taking my question. In AFib, could you elaborate on the rationale for the development plan? It looks like the Phase II ATLAS study
is going to complete after the Phase III EVEREST already start. So just how will you use the info that you learned from ATLAS? Thank you.
Question: Taylor Hanley - JPMorgan Chase & Co - Analyst
: Hi, this is Taylor Hanley on for Chris. So we were hoping to touch on, I guess, the broader Factor XI development landscape. And we are expecting
data from upcoming Phase III from some of your competitors Bayer and Bristol. I'm just wondering, would any success or setbacks with those trials
change how you'd approach your development programs? And how can you apply any of the learnings from their programs to your development
program? Thank you.
| 
